据证券之星公开数据整理，近期亚太药业（002370）发布2025年中报。截至本报告期末，公司营业总收 入1.52亿元，同比下降31.48%，归母净利润1.05亿元，同比上升1820.97%。按单季度数据看，第二季度 营业总收入8752.42万元，同比下降19.86%，第二季度归母净利润1.13亿元，同比上升1233.32%。本报 告期亚太药业三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达84.8%。 偿债能力：公司现金资产非常健康。 商业模式：公司业绩主要依靠营销驱动。需要仔细研究这类驱动力背后的实际情况。 财报体检工具显示： 建议关注财务费用状况（财务费用/近3年经营性现金流均值已达115.46%） 建议关注公司应收账款状况（应收账款/利润已达283.04%） 本次财报公布的各项数据指标表现一般。其中，毛利率31.66%，同比减0.58%，净利率69.16%，同比增 2703.45%，销售费用、管理费用、财务费用总计8446.33万元，三费占营收比55.54%，同比增84.8%，每 股净资产1.51元，同比增106.1%，每股经营性现金流0.04元，同比减29.66%，每股收益0.14 ...

Group 1 - The core viewpoint of the article is that Asia-Pacific Pharmaceutical (002370.SZ) reported a significant decline in revenue for the first half of 2025, while net profit showed a remarkable increase [1] - The company achieved operating revenue of 152 million yuan, representing a year-on-year decrease of 31.48% [1] - The net profit attributable to shareholders of the listed company was 105 million yuan, reflecting a year-on-year increase of 1,820.97% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -48.86 million yuan [1] - The basic earnings per share were reported at 0.14 yuan [1]

Company Performance - Asia-Pacific Pharmaceutical reported a revenue of approximately 152 million yuan for the first half of 2025, representing a year-on-year decrease of 31.48% [1] - The net profit attributable to shareholders of the listed company was approximately 105 million yuan, showing a significant year-on-year increase of 1820.97% [1] - Basic earnings per share increased to 0.14 yuan, reflecting a year-on-year growth of 1300% [1] Industry Context - The domestic market is witnessing the first A-level car exhibition in the second half of the year, with nearly 120 brands and 1600 vehicles participating, indicating a competitive landscape in the automotive sector [1]

Group 1 - The core point of the article is that Asia-Pacific Pharmaceutical (SZ 002370) held its fourth meeting of the eighth board of directors on August 28, 2025, where it reviewed the 2025 semi-annual report and its summary [1] - For the first half of 2025, the company's revenue composition shows that the pharmaceutical manufacturing sector accounted for 99.33%, while other businesses contributed 0.67% [1]

Company Announcements - SMIC plans to issue A-shares to acquire minority stakes in its subsidiary, SMIC North, leading to a temporary suspension of its stock trading for up to 10 trading days [1] - Huasheng Tiancheng's director and supervisor plan to reduce their holdings by up to 0.9984% of the total shares [2] - BYD reported a net profit of 15.51 billion yuan for the first half of the year, a year-on-year increase of 13.79% [2] - Changfei Fiber's net profit for the first half of the year was 296 million yuan, down 21.71% year-on-year [2] - Jia Yuan Technology plans to invest 500 million yuan to acquire part of the equity in Endatong, focusing on the optical module industry [1][17] - Guizhou Moutai completed the repurchase of 3.9276 million shares [1][19] Financial Performance - CEC reported a net profit of 24.641 billion yuan for the first half of the year, a decrease of 12% year-on-year [5] - Longjiang Power achieved a net profit of 13.056 billion yuan, up 14.86% year-on-year [8] - China Rare Earth reported a net profit of 162 million yuan, turning from a loss of 244 million yuan in the previous year [9] - Huayi Brothers' net profit increased by 48.34% to 2.028 billion yuan [6] - Wealth Trend's net profit grew by 6.61% year-on-year [24] Mergers and Acquisitions - Tailin Micro plans to acquire 100% of Panqi Micro's equity through a combination of cash and stock issuance [4] - Aishen Medical announced the acquisition of partial equity in three medical institutions for a total of 105 million yuan [18] Stock Movements - Guizhou Moutai's controlling shareholder plans to increase its stake by 3 to 3.3 billion yuan [15] - Ganfeng Lithium plans to invest 4 billion yuan to build a new lithium-ion battery manufacturing base [16] Market Developments - China National Offshore Oil Corporation won a bid for a project in Qatar worth approximately 4 billion USD [14] - Aishen Medical's acquisition of equity in medical institutions aims to enhance its service coverage and operational efficiency [18]

智通财经APP讯，亚太药业(002370.SZ)发布2025年半年度报告，该公司营业收入为1.52亿元，同比减少 31.48%。归属于上市公司股东的净利润为1.05亿元，同比增长1820.97%。归属于上市公司股东的扣除非 经常性损益的净亏损为4886.22万元，同比扩大524.31%。基本每股收益为0.14元。 ...

Core Viewpoint - Asia-Pacific Pharmaceutical disclosed a decrease in shareholder accounts and an increase in average shareholding quantity, indicating a shift in investor behavior despite a positive stock price performance during the reporting period [1][2]. Group 1: Shareholder Statistics - As of June 30, 2025, the number of shareholders for Asia-Pacific Pharmaceutical was 55,101, a decrease of 5,691 accounts, representing a reduction of 9.36% compared to March 31, 2025 [1][2]. - The average number of shares held per account increased from 12,200 shares to 13,500 shares, while the average market value of shares held per account was 51,400 yuan [1][2]. - The average number of shareholders in the chemical pharmaceutical industry was 32,900, indicating that Asia-Pacific Pharmaceutical's shareholder count is above the industry average [1]. Group 2: Stock Performance - From March 31, 2025, to June 30, 2025, Asia-Pacific Pharmaceutical's stock price increased by 14.11%, despite the reduction in shareholder accounts [1][2]. - During the same period, the company experienced a net inflow of 141 million yuan from institutional investors, while retail investors saw a net outflow of 56.45 million yuan [2].

证券代码：002370 证券简称：亚太药业 公告编号：2025-065 浙江亚太药业股份有限公司 关于第八届董事会第四次会议决议的公告 （二）以 9 票同意，0 票反对，0 票弃权，审议通过了《2025 年 半年度报告及其摘要》 本议案已经公司审计委员会审议通过。 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江亚太药业股份有限公司（以下简称"公司"）第八届董事会 第四次会议（以下简称"会议"）通知于 2025 年 8 月 18 日以专人送 达、微信等方式送达各位董事。 会议于 2025 年 8 月 28 日在公司办公楼三楼会议室以现场表决与 通讯表决相结合的方式召开。 本次会议的应表决董事 9 人，实际参与表决董事 9 人，其中董事 宋令波先生以通讯方式参与表决，公司监事、高级管理人员列席会议。 律、法规、规则及《公司章程》的有关规定。 二、董事会会议审议情况 （一）以 9 票同意，0 票反对，0 票弃权，审议通过了《关于计 提信用减值损失、资产减值损失的议案》 具体内容详见 2025 年 8 月 30 日公司在指定信息披露媒体《 ...

Group 1 - The company held its fourth meeting of the eighth supervisory board on August 28, 2025, with all three supervisors participating in the voting [1] - The supervisory board approved the proposal for credit impairment losses and asset impairment losses with a unanimous vote, stating that it aligns with accounting standards and reflects the company's actual situation [1] - The supervisory board also approved the 2025 semi-annual report and its summary, confirming that the report's preparation and review processes comply with legal and regulatory requirements [2]

Financial Overview - The company reported total revenue of CNY 152,074,731.41 for the first half of 2025, a decrease from CNY 221,933,271.08 in the same period of 2024, representing a decline of approximately 31.4% [4][5] - Total operating costs for the first half of 2025 were CNY 197,899,171.63, down from CNY 228,077,115.52 in the previous year, indicating a decrease of about 13.3% [4][5] - The net profit for the first half of 2025 was CNY 105,176,469.82, compared to a net profit of CNY 5,475,173.86 in the first half of 2024, showing a significant increase [5][6] Assets and Liabilities - Total assets at the end of the first half of 2025 amounted to CNY 1,504,030,958.30, down from CNY 1,757,857,969.48 at the beginning of the period, reflecting a decrease of approximately 14.4% [3][4] - Total liabilities decreased to CNY 318,614,658.60 from CNY 647,661,753.51, a reduction of about 50.8% [3][4] - The total equity attributable to shareholders increased to CNY 1,185,416,299.70 from CNY 1,110,196,215.97, marking an increase of approximately 6.7% [4][5] Cash Flow - The net cash flow from operating activities for the first half of 2025 was CNY 27,896,651.19, compared to CNY 32,398,357.90 in the same period of 2024, indicating a decrease [6][7] - Cash flow from investing activities showed a net inflow of CNY 175,946,706.63, a significant improvement from a net outflow of CNY 4,386,493.11 in the previous year [6][7] - Cash flow from financing activities resulted in a net outflow of CNY 314,596,678.34, compared to a net outflow of CNY 61,901,761.80 in the same period of 2024 [6][7] Earnings Per Share - Basic and diluted earnings per share for the first half of 2025 were both CNY 0.14, compared to CNY 0.01 in the same period of 2024, indicating a substantial increase in profitability per share [5][6]